Carmen Hidalgo Tenorio-rekin lankidetzan egindako argitalpenak (72)

2024

  1. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain

    Viruses, Vol. 16, Núm. 2

  2. The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers

    Journal of Clinical Investigation, Vol. 134, Núm. 8

2023

  1. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 3

  2. Isolation of Haemophilus no ducreyi in samples from the genital tract of men: Its clinical relationship

    Revista Internacional de Andrologia, Vol. 21, Núm. 4

2022

  1. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

    Viruses, Vol. 14, Núm. 3

  2. Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections

    Scientific Reports, Vol. 12, Núm. 1

  3. Incidence, Management Experience and Characteristics of Patients with Giardiasis and Common Variable Immunodeficiency

    Journal of Clinical Medicine, Vol. 11, Núm. 23

  4. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV

    Viruses, Vol. 14, Núm. 12

  5. Timing in antibiotic therapy: when and how to start, de-escalate and stop antibiotic therapy. Proposals from a stablished antimicrobial stewardship program

    Revista Espanola de Quimioterapia, Vol. 35, pp. 102-107

2021

  1. Effectiveness of the quadrivalent hpv vaccine in preventing anal ≥ hsils in a spanish population of hiv+ msm aged > 26 years

    Viruses, Vol. 13, Núm. 2

  2. Emerging presence of urethritis and balanitis by Pasteurella bettyae

    Infectious Diseases Now, Vol. 51, Núm. 5, pp. 492-494

  3. Risk factors for ≥high-grade anal intraepithelial lesions in MSM living with HIV and the response to topical and surgical treatments

    PLoS ONE, Vol. 16, Núm. 2 February

2020

  1. Genetic diversity of HIV in seminal plasma remains higher than in blood after short-term antiretroviral therapy

    Sexually Transmitted Infections, Vol. 96, Núm. 5, pp. 337-341

  2. Pharmacist recommendations for carbapenem de-escalation in urinary tract infection within an antimicrobial stewardship program

    Journal of Infection and Public Health, Vol. 13, Núm. 4, pp. 558-563

2019

  1. ART is key to clearing oncogenic HPV genotypes (HR-HPV) in anal mucosa of HIV-positive MSM

    PLoS ONE, Vol. 14, Núm. 10

  2. Clinical outcomes of carbapenem de-escalation regardless of microbiological results: A propensity score analysis

    International Journal of Infectious Diseases, Vol. 85, pp. 80-87

  3. DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

    Annals of Clinical Microbiology and Antimicrobials, Vol. 18, Núm. 1

  4. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients

    Medicine (United States), Vol. 98, Núm. 32

  5. Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: A preliminary

    BMC Infectious Diseases, Vol. 19, Núm. 1

  6. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort

    PLoS ONE, Vol. 14, Núm. 8